Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Apotex Paxil ANDA: Presence Of Hemihydrate Does Not Infringe GSK’s Patent

Executive Summary

Apotex' generic version of Paxil would not infringe GSK's hemihydrate paroxetine patent because the generic does not contain a commercially significant amount of hemihydrate crystals, a Chicago district court decision says

You may also be interested in...



Ivax Zyprexa Patent Challenge Could Benefit From Paxil Invalidity Ruling

Ivax believes its challenge to Lilly's Zyprexa patent will get a boost from a recent appellate court decision invalidating a GlaxoSmithKline patent claim for Paxil

Ivax Zyprexa Patent Challenge Could Benefit From Paxil Invalidity Ruling

Ivax believes its challenge to Lilly's Zyprexa patent will get a boost from a recent appellate court decision invalidating a GlaxoSmithKline patent claim for Paxil

PTO Tougher On Patent Claims Following Claritin Metabolite Ruling – Attorney

Patenting drug claims has become more difficult due to recent court rulings in Waxman/Hatch cases, attorney Anthony Insogna said during a panel discussion at the J.P. Morgan health care conference in San Francisco Jan. 14

Related Content

UsernamePublicRestriction

Register

PS041378

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel